Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

被引：2

作者：

Ferreri, Christopher J. ^{[1
]}

Quatela, Steven E. ^{[2
]}

Aina, Sean ^{[2
]}

Roy, Pourab ^{[2
]}

Boyapati, Anita ^{[2
]}

Lorenc, Karen Rodriguez ^{[2
]}

Kroog, Glenn S. ^{[2
]}

Orlowski, Robert Z. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-158396

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：10129 / 10130

页数：2

共 50 条

[21] A phase I/II study of davutamig (REGN5093), a METxMET bispecific antibody, in patients with MET-altered, advanced non-small cell lung cancer (aNSCLC): Trial in progress update [J].

Ahn, M-j. ;

Cho, B. C. ;

Kim, T. M. ;

Han, J-y. ;

Kim, C. ;

Shim, B. ;

Drilon, A. ;

Blumenschein, G. ;

Villaruz, L. ;

Gray, J. E. ;

Pujol, J-l. ;

Lena, H. ;

Moro-Sibilot, D. ;

Perez, J. ;

Modi, D. A. ;

Park, J. S. ;

Patel, S. ;

Li, S. ;

Kim, E. ;

Magnan, H. .

ANNALS OF ONCOLOGY, 2024, 35 :S1673-S1674

[22] A Multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: Efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. [J].

Richardson, P ;

Chanan-Khan, A ;

Schlossman, R ;

Munshi, N ;

Wen, P ;

Briemberg, H ;

Kuter, D ;

Oaklander, A ;

Lodial, S ;

Hassoun, H ;

Doss, D ;

Lunde, L ;

Hayes, S ;

McKenney, M ;

Hande, K ;

Lai, L ;

Freeman, A ;

Dinand, K ;

McAlister, C ;

Warren, D ;

Collins, D ;

Esseltine, D ;

Amato, A ;

Anderson, K .

BLOOD, 2005, 106 (11) :716A-716A

[23] Phase II testing of lenalidomide plus melphalan for previously untreated older patients with multiple myeloma: Toxicity data from the NCIC CTG MY.11 trial [J].

White, Darrell J. ;

Kovacs, Michael J. ;

Belch, Andrew ;

Stewart, Keith ;

Chen, Christine ;

Rubin, Sheldon ;

Macdonald, David A. ;

Harnett, Erica ;

Chapman, Judy-Anne W. ;

Shepherd, Lois E. ;

Meyer, Ralph M. .

BLOOD, 2007, 110 (11) :63A-63A

[24] Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study [J].

Sher, Taimur ;

Miller, Kena C. ;

Ailawadhi, Sikander ;

Manfredi, Debbie ;

Wood, Margaret ;

Tan, Wei ;

Wilding, Gregory ;

Liu, Hong ;

Czuczman, Myron S. ;

Hernandez, Francisco ;

Hong, Frederick ;

Sood, Raman ;

Soniwalla, Saif ;

Lawrence, William ;

Kouides, Peter A. ;

Lee, Kelvin P. ;

Chanan-Khan, Asher .

BLOOD, 2009, 114 (22) :256-256

[25] A phase I/II study of ubamatamab (REGN4018), a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab (anti-PD-1) in patients with recurrent ovarian cancer or MUC16+endometrial cancer: Trial in progress update [J].

Liu, Joyce ;

O'Malley, David ;

Van Nieuwenhuysen, Els ;

O'Cearbhaill, Roisin ;

Bouberhan, Sara ;

Moore, Kathleen ;

Hou, June ;

Hamilton, Erika ;

Yoo, Suk-Young ;

Wang, Bin ;

Peterman, Mary ;

Schmidt, Tamara ;

Knorr, David ;

Lowy, Israel ;

Uldrick, Thomas ;

Miller, Elizabeth .

GYNECOLOGIC ONCOLOGY, 2024, 190 :S284-S284

[26] PHASE-I-II TRIAL OF HIGH-DOSE MELPHALAN IN PREVIOUSLY UNTREATED STAGE-III MULTIPLE-MYELOMA - CANCER AND LEUKEMIA GROUP-B STUDY 8512 [J].

CASE, DC ;

COLEMAN, M ;

GOTTLIEB, A ;

MCCARROLL, K .

CANCER INVESTIGATION, 1992, 10 (01) :11-17

[27] Oral weekly MLN9708, an investigational proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma (MM): A phase I/II study. [J].

Richardson, Paul Gerard Guy ;

Berdeja, Jesus G. ;

Niesvizky, Ruben ;

Lonial, Sagar ;

Roy, Vivek ;

Hari, Parameswaran ;

Berg, Deborah ;

Liu, Guohui ;

Gupta, Neeraj ;

Di Bacco, Alessandra ;

Hui, Ai-Min ;

Kumar, Shaji .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

[28] Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study [J].

Segeren, CM ;

Sonneveld, P ;

van der Holt, B ;

Vellenga, E ;

Croockewit, AJ ;

Verhoef, GEG ;

Cornelissen, JJ ;

Schaafsma, MR ;

van Oers, MHJ ;

Wijermans, PW ;

Fibbe, WE ;

Wittebol, S ;

Schouten, HC ;

Kooy, MV ;

Biesma, DH ;

Baars, JW ;

Slater, R ;

Steijaert, MMC ;

Buijt, I ;

Lokhorst, HM .

BLOOD, 2003, 101 (06) :2144-2151

[29] A phase 1/2 study of REGN7075 (EGFRxCD28 costimulatory bispecific antibody) in combination with cemiplimab (anti-PD-1) in patients with advanced solid tumors, including colorectal cancer: Trial in progress update [J].

Segal, Neil Howard ;

Girda, Eugenia ;

Sohal, Davendra ;

Lakhani, Nehal J. ;

Olszanski, Anthony J. ;

Fong, Lawrence ;

Han, Hyunsil ;

Casey, Kerry A. ;

Li, Siyu ;

Ganguly, Samit ;

Seebach, Frank A. ;

Mathias, Melissa Divya ;

Pelster, Meredith .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) :TPS239-TPS239

[30] Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy [J].

Bannerji, Rajat ;

Brown, Jennifer R. ;

Advani, Ranjana H. ;

Arnason, Jon ;

O'Brien, Susan M. ;

Allan, John N. ;

Chavez, Julio C. ;

Barnes, Jeffrey A. ;

Joyce, Robin ;

Ansell, Stephen ;

Topp, Max S. ;

Adriaens, Lieve ;

Ufkin, Melanie ;

Kostic, Ana ;

Paccaly, Anne ;

Gao, Bo ;

Trail, Pamela A. ;

Lowy, Israel ;

Brownstein, Carrie .

BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →